Alexandre Chan
•Professor of Clinical Pharmacy, Department of Clinical Pharmacy Practice, University of California Irvine
•Joint Faculty (WOS), Department of Pharmaceutical Sciences, School of Pharmacy & Pharmaceutical Sciences, University of California Irvine
Biography
Alexandre Chan, PharmD, PhD, MPH, FCCP, FISOPP, BCPS, BCOP, APh, is a Professor of Clinical Pharmacy in the Department of Clinical Pharmacy Practice at the University of California, Irvine School of Pharmacy & Pharmaceutical Sciences, with joint appointments in the Department of Pharmaceutical Sciences and the Division of Hematology/Oncology in the School of Medicine. He also holds appointments as Adjunct Faculty at Duke-NUS Medical School. Prof. Chan's research is focused on cancer supportive care and survivorship, with particular emphasis on cancer-related cognitive impairment—including its biomarkers, neurotrophic mechanisms, and integrative oncology interventions such as electroacupuncture—as well as implementation science and population health approaches to symptom management in oncologically diverse patient populations.
Chan has authored over 340 peer-reviewed publications (h-index: 58) and has secured research funding from the National Institutes of Health/National Cancer Institute, the National Medical Research Council of Singapore, the Department of Defense, and numerous other national and international agencies. He has contributed to clinical practice guideline development through organizations including ASCO, ESMO, ISOPP, and MASCC, and serves as an Assistant Editor for Dipiro's Pharmacotherapy: A Pathophysiologic Approach. He currently serves as President-Elect of the Multinational Association of Supportive Care in Cancer (MASCC) and previously served as President of the International Society of Oncology Pharmacy Practitioners (ISOPP).
As Founding Department Chair at UCI, Chan assembled a faculty of more than 20 core professors and 40 volunteer professors to build and launch the Doctor of Pharmacy program, whose inaugural class graduated in May 2025. Earlier in his career, he held faculty and clinical appointments at the National University of Singapore and the National Cancer Centre Singapore, where he built a research program spanning North America and Asia over more than two decades. Chan received his PharmD from Rutgers University, his MPH from the National University of Singapore's Yong Loo Lin School of Medicine, and his PhD from Flinders University, Australia.
Return to topEducation
- PharmD, Ernest Mario School of Pharmacy, Rutgers University, 2004
- Pharmacy Practice Residency, University of California San Francisco, 2005
- Oncology Specialty Residency, University of California Davis Medical Center, 2006
- MPH in Clinical Epidemiology, Yong Loo Lin School of Medicine, National University of Singapore, 2011
- PhD, Flinders University, 2025
Distinctions
- ISOPP Helen McKinnon Award, 2024
- MASCC Innovator Award 2023, 2023
- Steven M. Grunberg Memorial Award, MASCC, 2015
- Fellow (Elected), International Society of Oncology Pharmacy Practitioners (FISOPP), 2018
- Fellow (Elected), American College of Clinical Pharmacy (FCCP), 2014
- ISOPP/JOPP Oncology Pharmacy Research Best Paper Award 2026, 2026
- HOPA 2025 Oncology Pharmacy Practice Literature Award, 2025
- HOPA 2024 Basic and Clinical Research Literature Award, 2024
- ACCP 2020 Adult Medicine PRN Outstanding Paper Award, 2020
- HOPA 2020 Oncology Pharmacy Practice Literature Award, 2020
Areas of Expertise
- Oncology Supportive Care and Survivorship
- Chemotherapy-Induced Nausea and Vomiting
- Cancer-Related Cognitive Impairment Biomarkers
- Pharmacoinformatics and Drug Interactions
- Electroacupuncture for Neuropsychiatric Symptom Clusters
- Patient-Reported Outcomes Implementation Science
- Neurotrophic Factor Augmentation Strategies
Recent Publications
- Ng DQ, Heshmatipour M, Trudeau J, Sridhar A, Pluimer B, Drayson OGG, Lavasani SM, Parajuli R, Lee S, Agrawal A, Acharya MM, Limoli CL, Harris RE, Xie L, Malik S, Chan A, “Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial”, Journal of the National Cancer Institute, pp. djag096, 2026.
- Olarewaju ML, Rahamon RB, Abolarin O, Asishana TK, Ibregbe R, Chan A, “Impact of healthcare providers' training (ISOPP-OPAB) on biosimilars use for cancer care at a university hospital in Nigeria” (opens in new tab), Journal of Oncology Pharmacy Practice, vol. 32, pp. 10781552261428431, 2026.
- Ramsey I, Crawford-Williams F, Thamm C, Aubel D, Bender JL, Chan A, Chin M, Fitch MI, Jefford M, Mbanugo E, Soto-Perez-de-Celis E, Taylor C, Chan RJ, “Developing a practice framework for patient navigation in cancer care: a Global Initiative to Advance Cancer Navigation for Better Outcomes (GINO) project” (opens in new tab), EClinicalMedicine, vol. 93, pp. 103808, 2026.
- Wong HCY, Hart NH, Chan A, Ee C, Thamm C, Chan RJ, “Global priorities for advancing cancer survivorship” (opens in new tab), Current Opinion in Oncology, vol. 38, no. 2, pp. 137-145, 2026.
- Baker WL, Chan A, “Harnessing the Power of Artificial Intelligence to Enhance Drug Therapy Research” (opens in new tab), Pharmacotherapy, vol. 46, no. 3, pp. e70105, 2026.
- DiDomenico RJ, Smith SE, Chan A, “A Roadmap for Studying the Impact of Pharmacist Board Certification on Patient Outcomes: Feasibility, Applicability, and Methodological Considerations” (opens in new tab), Jaccp Journal of the American College of Clinical Pharmacy, vol. 9, no. 2, pp. e70165, 2026.
- Haywood D, Chan A, Lustberg MB, Nekhlyudov L, Chan RJ, Anderson DJ, Dawson A, Gnatt I, Agar MR, Hart NH, “Planning for cancer: building accessible and high-quality survivorship care for all” (opens in new tab), Trends in Cancer, vol. 12, pp. S2405-8033(25)00313-9, 2026.
- Chan A., Chan D., Agrawal P., Beppu L.L., Kober K., Ng D.Q., Sayer M., Trudeau J., “Trajectory and predictors of cancer- and treatment-related fatigue (CRF) in adolescent and young adult cancer patients: a prospective, longitudinal study” (opens in new tab), BMC Cancer, vol. 26, 2026.
- Chan A., Kagramanov D., Nasr R., Asuzu C., Bao T., Cheung Y.T., Kwon J.H., Lacey J., Lee R.T., Lustberg M., Ohaeri B.M., Rao S., Soto-Perez-de-Celis E., Witt C.M., Lopez A.M., “Barriers to recommendation of integrative oncology modalities in supportive care: a MASCC/SIO survey” (opens in new tab), Supportive Care in Cancer, vol. 34, 2026.
- Ng D.Q., Zheng Z., Jemal A., Chan A., Islami F., “Sociodemographic disparities and reasons for delayed healthcare among U.S. cancer survivors: an All of Us study” (opens in new tab), Supportive Care in Cancer, vol. 34, 2026.
- Jan T., Chen M., Chan F.-Y., Kuderer N., Chan A., “Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California” (opens in new tab), Cancers, vol. 18, 2026.
- Hernandez K, Doh J, Lustberg M, Chan A, “Strengthening Supportive Care: Leveraging the Expanding Role of Oncology Pharmacists”, JCO Oncology Advances, vol. 2, pp. e2500180, 2025.
- Sayer M, Ng DQ, Trudeau J, Chan RJ, Acharya MM, Kober K, Chan A, “Epigenetic age acceleration and neurotrophin signaling pathways in cancer-related cognitive impairment: a longitudinal, prospective cohort study” (opens in new tab), Frontiers in Aging, vol. 6, pp. 1667638, 2025.
- Jefford M, Crawford-Williams F, Taylor C, Takahashi M, Lam WT, Chan A, Koczwara B, Lou Y, Chan RJ, “Global need regional action: opportunities to improve cancer survivorship care in the Western Pacific” (opens in new tab), Lancet Regional Health – Western Pacific, vol. 65, pp. 101748, 2025.
- Chan A, Nasr R, Arcos D, Kagramanov D, Asuzu C, Bao T, Cheung YT, Kwon JH, Lacey J, Lee RT, Lustberg M, Ohaeri BM, Rao S, Soto-Perez-de-Celis E, Witt CM, Lopez AM, “Evaluation of integrative oncology modalities for symptom management: a MASCC/SIO global survey” (opens in new tab), BMC Complementary Medicine and Therapies, vol. 25, no. 1, pp. 406, 2025.
- Ben Abid F, Cardeña-Gutiérrez A, Sathyanarayanan V, K M, Lustberg M, Soto-Perez-de-Celis E, Chan A, “Global disparities in supportive and survivorship care among adolescent and young adult cancer patients” (opens in new tab), Current Opinion in Supportive and Palliative Care, vol. 19, no. 4, pp. 263-269, 2025.
- Haywood D, Chan A, Chan RJ, Baughman FD, MclinPsych ED, Dhillon HM, Henneghan AM, Lawrence BJ, Lustberg MB, O'Connor M, Vardy JL, Rossell SL, Hart NH, “The MASCC COG-IMPACT: The COSA Endorsement of a MASCC Developed Unmet Needs Assessment Tool for Cancer-Related Cognitive Impairment Impact” (opens in new tab), Asia Pacific Journal of Clinical Oncology, vol. 22, pp. 3-7, 2025.
- Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Brem EA, Van Etten RA, Nelson EL, Coombs CC, Chan A, “R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 25, pp. e1014-e1021, 2025.
- Trudeau J, Ng DQ, Sayer M, Tan CJ, Ke Y, Chan RJ, Chan A, “Brain-derived neurotrophic factor and cytokines as predictors of cognitive impairment in adolescent and young adult cancer patients receiving chemotherapy: a longitudinal study” (opens in new tab), BMC Cancer, vol. 25, no. 1, pp. 1045, 2025.
- Ke Y, Fok RWY, Tan NC, Chew L, Wong WT, Kwan CS, Chung WL, Loh KW, Tan GSH, Cheng I, Lee JY, Chan A, “A Breast cAncer Survivorship Inter-Professional Community (BASIC) Shared Care Model to Promote Healthy Behaviors in Singapore: A Pilot Randomized Controlled Trial” (opens in new tab), International Journal of Behavioral Medicine, 2025.
Most Cited Publications
- Lee J, Chan A, “Polypharmacy in the elderly cancer patient: clinical implications and management” (opens in new tab), Lancet Oncology, vol. 12, no. 13, pp. 1249-5, 2011.
- Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A, “Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study” (opens in new tab), Annals of Oncology, vol. 26, no. 7, pp. 1446-51, 2015.
- Chan RJ, Gordon LG, Tan CJ, Chan A, Bradford NK, Yates P, Agbejule OA, Miaskowski C, “Relationships between Financial Toxicity and Symptom Burden in Cancer Survivors: A Systematic Review” (opens in new tab), Journal of Pain and Symptom Management, vol. 57, no. 3, pp. 646-660.e1, 2019.
- Teo YL, Ho HK, Chan A, “Metabolism-related pharmacokinetic drug-drug interactions in tyrosine kinase inhibitors: current understanding, challenges and recommendations” (opens in new tab), British Journal of Clinical Pharmacology, vol. 79, no. 2, pp. 241-5, 2015.
- Yap KYL, Chui WK, Chan A, “Drug interactions between chemotherapy regimens and antiepileptics” (opens in new tab), Clinical Therapeutics, vol. 8, pp. 1387-407, 2008.
- Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, van den Hurk C, Chan A, “The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews”, Annals of Oncology, vol. 32, pp. 1552-1570, 2021.
- Cheung Y.T., Foo Y.L., Shwe M., Tan Y.P., Fan G., Yong W.S., Madhukumar P., Ooi W.S., Chay W.Y., Dent R.A., Ang S.F., Lo S.K., Yap Y.S., Ng R., Chan A., “Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients” (opens in new tab), Journal of Clinical Epidemiology, vol. 67, pp. 811-820, 2014.
- Chan A, Chan D, Lee H, Ng CC, Yeo AHL, “Reporting adherence, validity and physical activity measures of wearable activity trackers in medical research: A systematic review” (opens in new tab), International Journal of Medical Informatics, vol. 160, pp. 104696, 2022.
- Toh YL, Ng T, Tan M, Tan A, Chan A, “Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review” (opens in new tab), Brain and Behavior, vol. 8, no. 7, pp. e01009, 2018.
- Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, et al., “Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer” (opens in new tab), Neuro Oncology, vol. 18, no. 2, pp. 244-51, 2016.
This profile was created with the help of AI.
Last updated on 10/2/2026.